Viridian Therapeutics, Inc.Viridian Therapeutics, Inc.Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.

No trades
See on Supercharts

Price target

39.560.000.00%
The 16 analysts offering 1 year price forecasts for VRDN have a max estimate of — and a min estimate of —.

Analyst rating

Based on 16 analysts giving stock ratings to VRDN in the past 3 months.

EPS

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise

Revenue

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions


VRDN EPS for the last quarter is −1.02 USD despite the estimation of −0.87 USD. In the next quarter EPS is expected to reach −1.06 USD. Track more of Viridian Therapeutics, Inc. financials and stay on top of what is up with the company.
In the next quarter Viridian Therapeutics, Inc. revenue is expected to reach ‪84.92 K‬ USD. Check out Viridian Therapeutics, Inc. revenue and earnings and make informed decisions.
According to analysts, VRDN price target is 39.56 USD with a max estimate of 61.00 USD and a min estimate of 22.00 USD. Check if this forecast comes true in a year, meanwhile watch Viridian Therapeutics, Inc. stock price chart and keep track of the current situation with VRDN news and stock market news.
We've gathered opinions of 16 analysts rating VRDN stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.